（来源：上观新闻） 12月23日下午，"聚力赋能，共创未来——临港集团生物医药产业专场对接会暨2025年度临创蓝湾基金 LP大会"在漕河泾会议中心圆满举行。本次大会聚焦生物医药核心赛道，致力于搭建园区产业与资本机 构精准对接、共生共赢的高端生态平台，为上海建设具有全球影响力的生物医药产业创新高地助力赋 能。中国科学院院士马大为、葛均波，市科委生物技术和医药处处长、二级巡视员曹宏明，临港集团副 总裁龚伟、总审计师熊国利，生物医药相关行业协会、产业发展联盟，投资机构以及企业代表出席活 动。 为强化创新投资赋能，临创资本与临创蓝湾基金向精准医学研究与产业发展联盟副主席、上海医学创新 发展基金会执行理事长王波、上海临床创新转化研究院副总裁王立言、国泰海通证券医疗健康行业负责 人王莉、道彤投资创始管理合伙人孙琦等行业顶尖专家颁发聘书，为基金投资决策、项目培育孵化、投 后管理赋能提供全方位支持。 现场，"核酸药物临床转化概念验证中心"正式启幕，标志着临港在生物医药细分赛道的生态布局进一步 完善。该中心由上海临床创新转化研究院和临港园区企业泰楚生物共同发起成立，聚焦核酸类创新药物 从早期研发到临床应用的转化瓶颈，构建覆盖核 ...

Core Insights - The conference focused on the biopharmaceutical industry, aiming to create a high-end ecological platform for industry and capital integration to support Shanghai's goal of becoming a global biopharmaceutical innovation hub [1] Group 1: Company Strategy and Development - Lingang Group has established 28 parks across 16 districts in Shanghai, housing over 24,000 enterprises, and is positioning itself as a leading service provider for innovative ecological integration in biopharmaceuticals [2] - The group emphasizes biopharmaceuticals as one of Shanghai's three strategic industries, with a focus on creating a "Life Blue Bay" in the Lingang New Area, fostering research and high-end manufacturing [2] - The company is transitioning from a "space provider" to an "ecosystem builder," leveraging a fund and base model to mobilize a fund scale of 170 billion yuan [2] Group 2: Industry Collaboration and Innovation - The "招投联动" (Investment and Recruitment Linkage) model is a key driver for empowering the biopharmaceutical ecosystem, integrating capital with industry innovation [4] - The establishment of the "Nucleic Acid Drug Clinical Transformation Concept Verification Center" aims to address bottlenecks in the development of nucleic acid drugs, providing comprehensive support from early research to clinical application [12] - The conference featured discussions on the internationalization of the biopharmaceutical industry, with insights from multinational companies and domestic innovators on building a comprehensive service system for global development [14] Group 3: Investment and Partnerships - Lingang Group's investment platform, including the Lingchuang Blue Bay Fund, has signed agreements with innovative companies like Tianchen Biotech and Orange Sail Medicine, focusing on dual-directional linkage between capital investment and industrial bases [8] - The partnership with Meifengli aims to integrate core advantages and resources in the medical device industry, enhancing the innovation service ecosystem in Shanghai [6] - The conference highlighted the importance of collaboration among industry experts to support investment decision-making and project incubation [10]